Kay G. Balster

Principal / Authorized signatory

Kay G. Balster

Principal / Authorized signatory

Kay Balster is one of High-Tech Gründerfonds’s longest-serving employees. Since 2009 he has been focusing on financing start-ups from the biotechnology and medical technology sectors. He can draw on 20 years of experience in advising technology start-ups, while his background in economics, training as a banker and especially the day-to-day interaction he has with the founders in his HTGF portfolio help him in his role.

When he is not working, family time and sport are his top priorities.

Contact

Telefon:
+49 – (0)228 – 82300 – 111

Portfolio

Posts & mentions

Press
12. January 2022

CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital

In the thriving field of neuroscience, CereGate is poised to revolutionize the treatment of neurological disorders by interacting with the human brain through a unique software-first approach. After making strides in the clinical development, including FDA Breakthrough designation for its first application in Deep Brain Stimulation Freezing of Gait Therapy (FOG-LIGHTS) and launching a clinical trial in the US, CereGate achieves additional funding to further accelerate the development of n
 
Press
21. October 2020

Successful exit for High-Tech Gründerfonds and Evonik Venture Capital – Synoste Oy becomes part of Globus Medical

Globus Medical, based in Audubon, Pennsylvania, USA, is a leading medical device manufacturerThe Finnish start-up Synoste, with offices in Helsinki and Düsseldorf, develops high-tech implants for minimally invasive treatment of leg length discrepancyThe transaction marks HTGF’s 11th successful exit during the coronavirus crisis High-Tech Gründerfonds (HTGF) and Evonik Venture Capital have exited Finnish start-up Synoste Oy. US based Globus Medical (NYSE: GMED) acquired all shares. Hig
 
Press
1. October 2020

Neuromodulation pioneer WISE closes EUR 15M Series C financing round
to launch second product, SCS EXPERT, for chronic pain

SCS EXPERT - first expandable percutaneous lead for neuromodulation treatment of chronic painNew investors, CDP Venture Capital and Eureka!, join existing participating investors in financing roundAdds to EUR 2.3M grant earlier in 2020 from the European Commission to launch SCS EXPERT WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C fi